Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00480532 · ClinicalTrials.gov registry record · NA

A Study of Continuous Oral Contraceptives and Doxycycline

A NA study of Contraceptives, Oral, sponsored by Oregon Health and Science University.

Completed
Registry status
NA
Development phase
131
Enrollment target
2
Study locations

NCT00480532 is a NA study of Contraceptives, Oral that has completed, run by Oregon Health and Science University. The registered enrollment target is 131 participants. The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00480532, a NA study of Contraceptives, Oral, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
NA
Development phase
131 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug, doxycycline, is an antibiotic used commonly for many conditions (i.e. acne, Chlamydia infections, pneumonia) and can be safely used on a daily basis. Doxycycline has been shown to decrease unplanned vaginal bleeding in progestin-only contraception but has not been studied in combined hormonal contraception.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Doxycycline
  • DRUG Oracea
  • DRUG Lybrel
  • DRUG Doxycycline 100bid x5 days at the time of bleeding

Study Locations (2)

Hawaii

  • University of Hawaii (UH) - Honolulu

Oregon

  • Oregon Health & Science University - Portland

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2007-05
Est. Completion 2011-05
Phase NA

What the Registry Record Tells You About NCT00480532

The ClinicalTrials.gov registry entry for NCT00480532 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Contraceptives, Oral appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT00480532 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Hawaii, Oregon.

Frequently Asked Questions

What is clinical trial NCT00480532 about?

NCT00480532 is a clinical study titled "A Study of Continuous Oral Contraceptives and Doxycycline". The purpose of this study is to learn if the study drug, doxycycline, can decrease the amount of unplanned vaginal bleeding that women commonly experience when taking combined oral contraception (COC)- pills with estrogen and progestin - in a continuous fashion - no hormone-free week. The study drug...

What is the current status of trial NCT00480532?

This trial is currently completed. It is a NA study. The enrollment target is 131 participants. The study started on 2007-05. Estimated completion is 2011-05.

What conditions does trial NCT00480532 study?

This clinical trial studies the following conditions: Contraceptives, Oral.

What interventions are being tested in trial NCT00480532?

The interventions under investigation include: Placebo (DRUG), Doxycycline (DRUG), Oracea (DRUG), Lybrel (DRUG), Doxycycline 100bid x5 days at the time of bleeding (DRUG).

Who is sponsoring clinical trial NCT00480532?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00480532 being conducted?

This trial has 2 study locations across Hawaii, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.